We marked our 5-year anniversary as a client of the London Bioscience Innovation Centre (LBIC) recently and featured in its Winter newsletter alongside Prokarium, MicrosensDx and VirTus and others.
2020 was certainly one of the most unusual years we can recall. Thank you to our clients, consultants and readers for following our news stories. We wrote on a range of topics and we recap the most widely read articles of last year in this short read.
PharmaMedic is delighted to announce the launch of a new series of virtual events starting with a breakfast briefing on Wednesday 10th February 2021 at 08:00 am. In this first event, we will cover the 2021 Medical and Regulatory Affairs Outlook. For full details and how to register please read further.
PharmaMedic was delighted to support and sponsor the Excellence in Rare Diseases and Orphan Drugs category at the recent PMEA awards. Read our article to find out more.
In our latest article, we explore how PMC supports Dr Kathrine Scott of Gedeon Richter with new product launches and day to day copy approval. Read on to learn how we are helping this small medical team make a real impact.
PharmaMedic Consultancy is delighted to announce its sponsorship of the ‘Excellence in Rare Diseases and Orphan Drugs" category at the 2020 Pharmaceutical Market Excellence Awards (PMEA).
From 1 January 2021, the Medicines and Healthcare products Regulatory Agency (MHRA) will be making independent regulatory decisions. Guidelines are in place, and the ABPI has called for support to help sponsors navigate the changes. Read on to learn more about this new era of independence for the agency.
In our latest article, we explore how PharmaMedic Consultancy (PMC®) supports Glenmark Pharmaceuticals with their day to day promotional activities. Read on to learn how our medical affairs consultant seamlessly fits into our client's team and ensures commercial compliance.
Collaboration is essential to drive innovation in pharma and bring new medicines to patients. In this article, we discuss how close cooperation between regulatory and medical affairs helps to streamline regulatory interactions.
Now more than ever, we need to apply old-fashioned common sense to help drive advances in healthcare. In this article we discuss how reconfiguring and repurposing of medicines have come to the fore during the COVID-19 pandemic.
